Open Access

A case of occult intrahepatic cholangiocarcinoma diagnosed by autopsy

  • Eri Oda1,
  • Daisuke Hashimoto1,
  • Yuko Shiomi2, 3,
  • Koji Ohnishi3,
  • Hiromitsu Hayashi1,
  • Akira Chikamoto1,
  • Motohiro Takeya3 and
  • Hideo Baba1Email author
Surgical Case Reports20151:101

DOI: 10.1186/s40792-015-0106-5

Received: 7 May 2015

Accepted: 6 October 2015

Published: 14 October 2015

Abstract

Cancer of unknown primary is associated with unknown biology and dismal prognosis. The most common primary sites of cancer of unknown primary were usually the lungs in autopsy studies, and intrahepatic cholangiocarcinoma is rare. We describe the case of a 57-year-old male patient with systemic lymph node metastasis. Imaging examination failed to reveal primary cancer; however, immunostaining of cytokeratins 7, 19, and 20 of a metastatic axillary lymph node suggested a pancreaticobiliary cancer as a primary lesion. He died of liver abscess and sepsis, and then, autopsy indicated occult intrahepatic cholangiocarcinoma. We discuss the clinical course of this rare cholangiocarcinoma including the diagnostic procedure and also present a review of the English literature regarding patients with cancer of unknown primary.

Keywords

Cancer of unknown primary Intrahepatic cholangiocarcinoma Autopsy

Background

Carcinomas of unknown primary (CUP) represent a group of heterogeneous tumors that has no identifiable origin [1]. Despite advances in tumor pathology and imaging techniques, such as positron emission tomography (PET), CUP account for about 5 % of all cancers [24] and are associated with a dismal prognosis [58]. In such CUP cases, an autopsy is performed to find the primary site.

In this report, we describe the case of a 59-year-old male patient with CUP. The patient was diagnosed with occult intrahepatic cholangiocarcinoma by autopsy. We present a review of the English literature regarding patients with cancer of unknown primary and discuss the clinical course and diagnostic examination for this occult cholangiocarcinoma case.

Case presentation

A 57-year-old male was investigated because of elevation of tumor markers (carcinoembryonic antigen (CEA) 12.9 mg/ml, carbohydrate antigen 19-9 (CA19-9) 658.5 U/ml). Enhanced computed tomography (CT) (Fig. 1a) and PET-CT (Fig. 1b) and endoscopy failed to detect a suspected primary lesion. As CT revealed multiple swollen abdominal (Fig. 1c) and axillary lymph nodes (Fig. 2a), an excisional biopsy of an axillary lymph node was performed. The histological diagnosis of the lymph node was a metastasis of adenocarcinoma (Fig. 2b). Because immunohistochemistry of the lymph node for cytokeratin (CK) 7 (Fig. 2c) and CK19 was positive and that for CK20 was almost negative (Fig. 2d), pancreaticobiliary cancer was suspected as primary lesion. Then, endoscopic retrograde cholangiopancreatography (ERCP) was performed; nevertheless, the primary lesion was not discovered. Biopsy from epithelium of the bile duct was obtained during ERCP, and the malignant cell was not found. Combination chemotherapy of gemcitabine and cisplatin was introduced; however, his disease had progressed. The patient died of liver abscess and sepsis 10 months after the introduction of chemotherapy. All diagnostic modalities which the patient underwent to obtain a diagnosis are listed in Table 1.
Fig. 1

Enhanced CT and PET-CT. CT (a) and PET-CT (b) failed to detect the tumor in the liver. CT revealed multiple swollen abdominal lymph nodes (arrows) (c)

Fig. 2

An excisional biopsy of axillary lymph node. CT (a) detected a swollen axillary lymph node (arrow) and an excisional biopsy was performed. The histological diagnosis of the lymph node was a metastasis of adenocarcinoma (b). Immunohistochemistry for CK7 was positive (c) and that for CK20 was almost negative (d). Bar 10 μm

Table 1

Diagnostic modalities which the patient underwent to obtain a diagnosis

Examination

Findings

Tumor marker

CEA 12.9 mg/ml

CA19-9 658.5 U/ml

Gastrointestinal and colorectal endoscopy

No significant findings

CT

Multiple swollen abdominal and axillary lymph nodes

PET-CT

Multiple swollen abdominal and axillary lymph nodes without abnormal uptake

Immunohistochemistry of the lymph node

CK7 and CK19 were positive

CK20 was almost negative

ERCP

No significant findings

Biopsy from epithelium of the bile duct

No malignancy

Autopsy was performed to find the primary lesion. Macroscopically, a gray-white colored, ill-defined solid tumor in the lateral segment of the liver was found, invading the diaphragm (Fig. 3a). Pathological diagnosis was intrahepatic cholangiocarcinoma (Fig. 3b). Immunohistochemistry revealed that these tumor cells were positive for CK7 (Fig. 3c) and CK19 and were negative for CK20 (Fig. 3d), as well as axillary lymph node metastasis.
Fig. 3

Postmortem findings. Macroscopically, a solid tumor (arrowheads) in the lateral segment of the liver was discovered (a). At histology, intrahepatic cholangiocarcinoma was observed (b). Immunohistochemistry of the lymph node for CK7 (c) and CK20 (d) was similar. Bar 10 μm

We reviewed recent English literature regarding patients with CUP [912] (Table 2). The most common pathology of CUP was adenocarcinoma, and the most common primary sites found by autopsy were usually the lungs followed by the pancreas. The possible reason why the lung is the common primary site in CUP is that small cell carcinoma is likely to develop metastasis even in its early stages [13]. However, we are not aware of similar cases with intrahepatic cholangiocarcinoma. The advantages of an autopsy in such cases are to identify the primary site, to provide closure for family members, and to correlate findings with antemortem investigations [9, 14, 15], in spite of the damaging disadvantage of the body. Autopsy can still play an important role, especially the problem-oriented autopsy in which a clinician provides clinical diagnoses and raises a specific question to be answered by the pathologist, like the present case [16, 17].
Table 2

Recent literature summary of studies of patients with cancer of unknown primary

Author

Total number of patients

Common pathology (no.)

Autopsy cases

Primary site identified

Common primary site (no.)

Blaszyk [10]

64

Adenocarcinoma (51), squamous carcinoma (3)

64

35

Pancreas (13), intestine (11), lung (8), ovaries (1), prostate (1)

Mayordomo [11]

43

Adenocarcinoma (23), undifferentiated (4), squamous carcinoma (3)

43

35

Bile duct (7), pancreas (6), lung (4), prostate (3), stomach (2)

Maiche [12]

109

Adenocarcinoma (37), squamous carcinoma (33), undifferentiated (31)

64

43

Lung (13), kidney (6), pancreas (4), intestine (4), liver (3)

Al-Brahim [9]

53

Adenocarcinoma (37), undifferentiated (5)

53

27

Lung (7), pancreas (4), stomach (3), bile duct (1), appendix (1)

The reason why we failed to detect this intrahepatic cholangiocarcinoma using many imaging modalities is considered as follows. Because cardiac pulsation can interfere with diagnostic imaging, it may be difficult to detect the solid tumor in the subphrenic area of the lateral segment of the liver. This area should be considered as one of the blind spots of imaging examination. There were no abnormal findings which could indicate the existence of the cancer lesion from the retrospective viewpoints. If an exploratory laparoscopy was performed, we might have found this intrahepatic cholangiocarcinoma. The result of the immunohistochemistry of the axillary lymph node was accurate in this case, so the treatment choice of chemotherapy with gemcitabine and cisplatin was adequate.

Conclusions

Despite advances in diagnostic imaging technology, identifying the primary sites in patients with metastatic malignancies is sometimes difficult even now. In the presented case, immunohistochemistry was accurate and useful, and exploratory laparoscopy may play a significant role to detect the primary lesion. Thus, various examinations should be performed for CUP patients to receive sufficient treatment.

Consent

Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Abbreviations

CA19-9: 

carbohydrate antigen 19-9

CEA: 

carcinoembryonic antigen

ERCP: 

endoscopic retrograde cholangiopancreatography

CT: 

computed tomography

CUP: 

carcinomas of unknown primary

PET: 

positron emission tomography

Declarations

Acknowledgements

No funding was received for this study.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Authors’ Affiliations

(1)
Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University
(2)
Division of Surgical Pathology, Graduate School of Medical Sciences, Kumamoto University
(3)
Department of Cell Pathology, Graduate School of Medical Sciences, Kumamoto University

References

  1. Pentheroudakis G, Briasoulis E, Pavlidis N. Cancer of unknown primary site: missing primary or missing biology? Oncologist. 2007;12:418–25.View ArticlePubMedGoogle Scholar
  2. Tsuya A, Kurata T, Tamiya A, Okamoto I, Ueda S, Sakai D, Sugimoto N, Matsumoto K, Goto I, Yamamoto N, Fukuoka M, Nakagawa K. A phase II study of cisplatin /S-1 in patients with carcinomas of unknown primary site. Invest New Drugs [Epub ahead of print].Google Scholar
  3. Hainsworth JD, Greco FA. Treatment of patients with cancer of an unknown primary site. N Engl J Med. 1993;329:257–63.View ArticlePubMedGoogle Scholar
  4. Greco FA. Molecular diagnosis of the tissue of origin in cancer of unknown primary site: useful in patient management. Curr Treat Options Oncol. [Epub ahead of print].Google Scholar
  5. Randén M, Rutqvist LE, Johansson H. Cancer patients without a known primary: incidence and survival trends in Sweden 1960–2007. Acta Oncol. 2009;48:915–20.View ArticlePubMedGoogle Scholar
  6. Dova L, Pentheroudakis G, Georgiou I, Malamou-Mitsi V, Vartholomatos G, Fountzilas G, et al. Global profiling of EGFR gene mutation, amplification, regulation and tissue protein expression in unknown primary carcinomas: to target or not to target? Clin Exp Metastasis. 2007;24:79–86.View ArticlePubMedGoogle Scholar
  7. Thomassen I, Verhoeven RH, van Gestel YR, van de Wouw AJ, Lemmens VE, de Hingh IH. Population-based incidence, treatment and survival of patients with peritoneal metastases of unknown origin. Eur J Cancer [Epub ahead of print].Google Scholar
  8. Riihimäki M, Hemminki A, Sundquist K, Hemminki K. Time trends in survival from cancer of unknown primary: small steps forward. Eur J Cancer. 2013;49:2403–10.View ArticlePubMedGoogle Scholar
  9. Al-Brahim N, Ross C, Carter B, Chorneyko K. The value of postmortem examination in cases of metastasis of unknown origin—20-year retrospective data from a tertiary care center. Ann Diagn Pathol. 2005;9:77–80.View ArticlePubMedGoogle Scholar
  10. Blaszyk H, Hartmann A, Bjornsson J. Cancer of unknown primary: clinicopathologic correlations. APMIS. 2003;111:1089–94.View ArticlePubMedGoogle Scholar
  11. Mayordomo JI, Guerra JM, Guijarro C, García-Prats MD, Gómez A, López-Brea M, et al. Neoplasms of unknown primary site: a clinicopathological study of autopsied patients. Tumori. 1993;79:321–4.PubMedGoogle Scholar
  12. Maiche AG. Cancer of unknown primary. A retrospective study based on 109 patients. Am J Clin Oncol. 1993;16:26–9.View ArticlePubMedGoogle Scholar
  13. Lobins R, Floyd J. Small cell carcinoma of unknown primary. Semin Oncol. 2007;34:39–42.View ArticlePubMedGoogle Scholar
  14. McPhee SJ. Maximizing the benefits of autopsy for clinicians and families. What needs to be done. Arch Pathol Lab Med. 1996;120:743–8.PubMedGoogle Scholar
  15. McPhee SJ. The autopsy. An antidote to misdiagnosis. Medicine. 1996;75:41–3.View ArticlePubMedGoogle Scholar
  16. Zarbo RJ, Baker PB, Howanitz PJ. The autopsy as a performance measurement tool—diagnostic discrepancies and unresolved clinical questions: a College of American Pathologists Q-Probes study of 2479 autopsies from 248 institutions. Arch Pathol Lab Med. 1999;123:191–8.PubMedGoogle Scholar
  17. Bayer-Garner IB, M Fink L, Lamps LW. Pathologists in a teaching institution assess the value of the autopsy. Arch Pathol Lab Med. 2002;126:442–7.PubMedGoogle Scholar

Copyright

© Oda et al. 2015